AzTrials
AzTrials

Prostate CancerPhase 1/2NCT03910660

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

A Phase 1/2 study testing BXCL701 plus Pembrolizumab and BXCL701 monotherapy in people with Prostate Cancer and Neuroendocrine Tumors, run by BioXcel Therapeutics Inc at 12 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

An open-label, multicenter, Phase 1b/2 study to identify the recommended Phase 2 dose and assess the efficacy and safety of BXCL701 administered orally, as monotherapy and in combination with PEMBRO, in patients with mCRPC. Read more about this study

Who is it for?
Ages 18 years and older, men only
What is being tested?
BXCL701 plus Pembrolizumab and BXCL701 monotherapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
98 participants
Where
12 sitesin 2 countries
Study dates
12 Feb 2019to 31 Aug 2025
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All patients must satisfy the following inclusion and exclusion criteria to be eligible for entry into the trial.
  • Patient has evidence of progressive, metastatic castration-resistant disease, as defined by PCWG3 criteria.
  • Patients with de novo small cell prostate cancer are not required to have received androgen deprivation therapy (ADT).
  • Progression during or following completion of at least 1 prior line of systemic therapy for locally advanced or metastatic prostate cancer.
  • Phases 2a and 2b Only:
  • SCNC - Cohort A of Phase 2a only:
Show all 33Show fewer
  • Patient has histologic evidence of SCNC either with archival tissue or a fresh tumor biopsy obtained during screening. Tumor biopsy tissue must be submitted for a central laboratory pathology review; however, enrollment can proceed if SCNC is determined by a local pathology review.
  • Patient has previously received at least 1 prior line of cytotoxic chemotherapy. Patients who either have refused chemotherapy or are considered unsuitable for chemotherapy may be eligible following discussion with the sponsor.
  • Must be willing to undergo metastatic tumor biopsy during Screening. Requirement may be waived in patients without safely accessible lesion or for patients with evaluable archival metastatic tumor tissue
  • Has measurable disease per RECIST 1.1 criteria.
  • Adenocarcinoma - Cohort B of Phase 2a; randomized population for Phase 2b
  • Patient has histologically or cytologically confirmed adenocarcinoma of the prostate without small cell neuroendocrine features.
  • Patients with soft tissue disease must provide a fresh core or excisional biopsy or archival tissue from a site not previously irradiated for central pathology review; however enrollment may proceed if predominant adenocarcinoma without small cell neuroendocrine features is determined by local pathology review.
  • Has been treated with at least 1 but no more than 2 second generation AR pathway target agents (e.g., abiraterone acetate and/or enzalutamide or other next generation agent) and at least 1 regimen/line of taxane containing chemotherapy in the mCSPC or mCRPC setting. Patients with known actionable mutations should have progressed on applicable standard care targeted therapy or have documented intolerance to or be unsuitable for such therapy.
  • RECIST 1.1 measurable disease or detectable bone metastases by whole body bone scintigraphy.
  • Patient has serum testosterone <50 ng/dL during Screening except for those with de novo small cell prostate cancer.
  • Patients with treatment-emergent SCNC without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analog during the course of protocol therapy except for patients with de novo small cell prostate cancer.
  • Patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Patient is ≥18 years of age.
  • Patient's acute toxic effects of previous anticancer therapy have resolved to ≤Grade 1 except for Grade 2-3 peripheral neuropathy or any grade of alopecia.
  • Patient has adequate baseline organ function, as demonstrated by the following:
  • Serum creatinine ≤1.5 times institutional upper limit of normal (ULN) or calculated creatinine clearance >50 mL/min;
  • Serum albumin ≥2.5 g/dL;
  • Total bilirubin ≤1.5 × ULN;
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × institutional ULN (patients with hepatic metastases must have AST/ALT ≤5 × ULN).
  • Patient has adequate baseline hematologic function, as demonstrated by the following:
  • Absolute neutrophil count (ANC) ≥1.5 × 109/L.
  • Hemoglobin ≥8 g/dL and no red blood cell transfusions during the prior 14 days.
  • Platelet count ≥100 × 109/L and no platelet transfusions during the prior 14 days.
  • Male patients and their female partners of childbearing potential must agree and commit to use a barrier contraception throughout the duration of the study until at least 6 months following the last dose of study drug, in addition to their female partners using either an intrauterine device or hormonal contraception and continuing until at least 6 months following the last dose of study drug. This criterion may be waived for male patients who have had a vasectomy >6 months before signing the informed consent form.
  • Exception: In the United States, female partners of study participants are not required to use contraception as a condition of their partners' eligibility, but female partners with child bearing potential should consider use of effect methods of contraception for the duration of their male partners' study participation and for at least 6 months following the last dose of study medication.
  • Patient has signed informed consent prior to initiation of any study-specific procedures or treatment.
  • Patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for overall survival (OS).

Who cannot join

  • Patient has received treatment with >2 cytotoxic chemotherapy regimens for castration-resistant prostate cancer (CRPC). Chemotherapy in the hormone-sensitive setting does not count in this assessment provided the last dose was >6 months before study entry. A change in chemotherapy agents due to intolerance after brief exposure may not count in this assessment, pending review with Medical Monitor.
  • Patient has received external-beam radiation or another systemic anticancer therapy within 14 days or 5 half-lives, whichever is shorter, prior to study treatment.
  • Patient has received treatment with an investigational systemic anticancer agent within 14 days prior to study drug administration.
  • Patient has received prior treatment with an anti-PD-1, anti-PD-L1, anti-programmed death ligand 2 (PD-L2) agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T lymphocyte-associated antigen 4 [CTLA-4], OX-40, CD137) or requires concomitant treatment with DPP4 inhibitors.
  • Patient has an additional active malignancy that may confound the assessment of the study endpoints. If the patient has a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence, this must be discussed with the sponsor before study entry. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer and carcinomas in situ (including transitional cell carcinoma, anal carcinoma, and melanoma in situ).
  • Patient has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
Show all 16Show fewer
  • QT interval corrected for heart rate using Bazett's formula (QTcB) >480 msec at Screening.
  • Patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the investigator would put the patient at significant risk for pulmonary complications during the study.
  • Patient has brain or leptomeningeal metastases that are symptomatic and progressive on imaging. Patients with a history of central nervous system (CNS) metastases must have received appropriate treatment. Central nervous system imaging is not required prior to study entry unless there is a history of CNS involvement or clinical suspicion of CNS involvement. Imaging of patients with a prior history of CNS metastases should be compared to prior imaging to discern disease progression.
  • Patient has an active autoimmune disease or Grade ≥3 non-infectious pneumonitis that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) or treatment with drugs (e.g., neomercazol, carbimazole) that function to decrease the generation of thyroid hormone by a hyperfunctioning thyroid gland (e.g., in Graves' disease) is not considered a form of systemic treatment of an autoimmune disease.
  • Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a prednisone equivalent dose of >10 mg daily for at least 1 week or other form of immunosuppressive therapy within 7 days prior to Cycle 1 Day 1 (C1D1).
  • Patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, suspected or active SARS-CoV-2 (COVID-19) infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Patient has known positive status for human immunodeficiency virus, active or chronic Hepatitis B, or Hepatitis C. Screening is not required.
  • Patient has any medical condition which, in the opinion of the investigator, places the patient at an unacceptably high risk for toxicity.
  • Any dysphagia, odynophagia, esophageal dysmotility or stricture, known GI malabsorption syndrome, or intractable diarrhea that may significantly alter the absorption of orally administered study drug.
  • Patients with history of symptomatic orthostatic hypotension within 3 months prior to enrollment. Orthostatic hypotension is defined as a drop in systolic blood pressure (BP) of ≥ 20 mmHg or diastolic BP of ≥ 10 mmHg with assumption of an upright posture.

Trial locations and contacts

12 sites in 2 countries.

12 sites in 2 countries

United States9 sites

  • The Ohio State University

    Columbus, Ohio, 43210

  • BioXcel Clinical Research Site

    Denver, Colorado, 80211

  • BioXcel Clinical Research Site

    Detroit, Michigan, 48201

  • Center for Advanced Medicine / R.J. Zuckerberg Cancer Center (Northwell Health Cancer Institute)

    Lake Success, New York, 11042

  • Yale University

    New Haven, Connecticut, 06510

  • Weill Cornell Medicine New York

    New York, New York, 10021

  • University of California San Francisco (UCSF)

    San Francisco, California, 94158

  • Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612

  • White Plains Hospital Center for Cancer Care

    White Plains, New York, 10601

Other trials in United States

United Kingdom3 sites

  • BioXcel Clinical Research Site

    Glasgow, England, G12 0YN

  • BioXcel Clinical Research Site

    London, Great Britain, W1T 7HA

  • BioXcel Clinical Research Site

    Sutton, Surrey, SM2 5NG

Other trials in United Kingdom

About this study

Official title: Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype

An open-label, multicenter, Phase 1b/2 study to identify the recommended Phase 2 dose and assess the efficacy and safety of BXCL701 administered orally, as monotherapy and in combination with PEMBRO, in patients with mCRPC. Patients enrolled in the Phase 2a portion of the study will have either Small Cell Neuroendocrine Prostate Cancer(SCNC)(Cohort A) or adenocarcinoma phenotype (Cohort B), while the Phase 2b randomized portion of the study will enroll only the histologic subtype(s) showing preliminary evidence in Phase 2a. The study will also assess other efficacy parameters, such as rPFS, PSA PFS, OS, and DOR, as well as the safety of the combined treatment. The study will consist of three components.

Read the detailed description

An open-label, multicenter, Phase 1b/2 study to identify the recommended Phase 2 dose and assess the efficacy and safety of BXCL701 administered orally, as monotherapy and in combination with PEMBRO, in patients with mCRPC. Patients enrolled in the Phase 2a portion of the study will have either Small Cell Neuroendocrine Prostate Cancer(SCNC)(Cohort A) or adenocarcinoma phenotype (Cohort B), while the Phase 2b randomized portion of the study will enroll only the histologic subtype(s) showing preliminary evidence in Phase 2a. The study will also assess other efficacy parameters, such as rPFS, PSA PFS, OS, and DOR, as well as the safety of the combined treatment. The study will consist of three components.

  1. Phase 1b: Safety and tolerability of the combination of BXCL701 administered once daily (QD) on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered intravenously (IV) on Day 1 of every 21 days will be assessed and confirmed in patients with mCRPC. In the first cohort enrolled in the study, the initial dose level of BXCL701 will be 0.4 mg; if there are no safety concerns, this will be escalated to a total daily dose of 0.6 mg.
  2. Phase 2a (Simon 2 Stage): Patients will be treated with BXCL701 in combination with PEMBRO. Patients will be grouped in 1 of 2 cohorts based on phenotype.
  • Cohort A: Patients with any Small Cell/Neuroendocrine features, either de novo or treatment-emergent included mixed SCNC.
  • Cohort B: Cohort B: Patients with adenocarcinoma and no evidence of small cell or neuroendocrine features.

Phase 2b (for the histologic subtype[s] showing preliminary efficacy in Phase 2a): Patients within a given subtype will be randomized 2:1 to receive either BXCL701 combined with PEMBRO or BXCL701 monotherapy.

Phase 1b:

Patients will be observed for dose-limiting toxicity (DLT) during Cycle 1. Three patients will be treated initially with BXCL701 0.4 mg plus PEMBRO:

  • If there are no DLTs in Cycle 1, the dose of BXCL701 will be escalated to a total daily dose of 0.6 mg in the next cohort of 3 patients.
  • If ≥1 of the 3 original patients has a DLT in Cycle 1, after a discussion between the sponsor and the investigator, either 3 patients (if 1 patient experiences a DLT) or 6 to 9 patients (if 2 or 3 patients experiences a DLT) will be added at the 0.4 mg BXCL701 dose level. For this expanded 0.4 mg cohort:
  • If none of the patients experience a DLT, consideration will be given to dose escalation to BXCL701 0.6 mg plus PEMBRO
  • If 1/3 of the patients experience a DLT, the Phase 2 can commence
  • If >1/3 of the patients experience a DLT, a discussion will be held between the investigators and sponsors as to how to proceed.

Following dose escalation to BXCL701 0.6 mg plus PEMBRO in 3 patients:

  • If there are no DLTs at this dose level, the Phase 2a can commence.
  • If ≥1/3 patients have a DLT in Cycle 1, after a discussion between the sponsor and the investigator, 6 to 9 patients will be added at the 0.6 mg BXCL701 total daily dose level; and consideration of an alternate dosing (e.g., split dose) schedule may be given.
  • For this additional cohort of 6 to 9 patients:
  • If </= 1/3 of the patients experience a DLT, the Phase2a can commence.
  • If >1/3 of the patients experience a DLT, consideration will be given to the use of a 0.4 mg total daily dose of BXCL701, or an intermediate dose, plus PEMBRO in the Phase 2a.
Being tested
BXCL701 plus Pembrolizumab, BXCL701 monotherapy
Medical subject headings
Prostatic Neoplasms, Neuroendocrine Tumors, Carcinoma, Small Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BXCL701 plus PembrolizumabDrug

    Also called BXCL701 plus Pembro

    BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.

    BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.

    BXCL701 should not be taken on an empty stomach.

    On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.

    The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle.

  • BXCL701 monotherapyDrug

    Also called BXCL701

    BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.

    BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.

    BXCL701 should not be taken on an empty stomach.

    On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.

Study groups in NCT03910660
Study groupRoleWhat they receive
Phase 1bOtherPatients will be observed for dose-limiting toxicity (DLT) during Cycle 1. 3 patients will be treated initially with 0.4 mg BXCL701 plus PEMBRO: If there are no DLTs, the dose of BXCL701 will be escalated to 0.6 mg in the next cohort. If ≥1/3 of patients has a DLT in Cycle 1, either 3 patients (if 1 experience a DLT) or 6 to 9 patients (if 2 or 3 experiences a DLT) will be added at the 0.4 mg dose. At the 0.4mg dose: If <1/3 of the patients experience a DLT, consideration will be given to dose to 0.6 mg BXCL701 plus PEMBRO. If 1/3 of the patients experience a DLT, the Phase 2a can commence. If >1/3 of the patients experience a DLT, a discussion will be held as to how to proceed. Following 0.6 mg dose. If there are no DLTs, the Phase 2a can commence. If ≥1/3 patients have a DLT in Cycle 1, after a discussion, 6 to 9 patients will be added at the 0.6 mg dose. For this cohort of 6 to 9 patients: If </=1/3 of the patients experience a DLT, the Phase 2a can commence
Receives: Drug: BXCL701 plus Pembrolizumab
Phase 2aOtherAfter assessment of the safety and confirmation of the BXCL701/+PEMBRO dose schedule to be used in the subsequent stage, the Phase 2a will begin. Eligible patients will receive BXCL701 QD on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 every 21 days.
Receives: Drug: BXCL701 plus Pembrolizumab
Phase 2b combinationOtherUpon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype, the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive: • Combination therapy of BXCL701 on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 of every 21 days.
Receives: Drug: BXCL701 plus Pembrolizumab
Phase 2b monotherapyOtherUpon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype, the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive: * Monotherapy BXCL701 on Days 1 to 14 of a 21-day cycle. Upon radiographic disease progression with monotherapy, crossover to combination treatment is allowed.
Receives: Drug: BXCL701 monotherapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Phase 2a: Estimate the composite response rate of the combination of BXCL701 + PEMBRO

    Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; circulating tumor cell (CTC) conversion from >5/7.5 mL to <5/7.5 mL per Veridex assay; and 50% or greater prostate-specific antigen (PSA) decline from baseline.

    Measured: up to 36 months

  2. Phase 2b: Evaluate response rates in patients treated with the combination of BXCL701 + PEMBRO and with BXCL701 monotherapy

    To evaluate the response rates, defined by RECIST 1.1 criteria, by histologic subtype in patients treated with the combination of BXCL701 + PEMBRO and with BXCL701 monotherapy.

    Measured: up to 36 months

Secondary outcomes (8)

  1. Phase 2a: Estimate the median radiographic progression-free survival (rPFS) of the combination of BXCL701 and PEMBRO in Cohort A and B

    The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro determined by radiographic evidence.

    Measured: up to 36 months

  2. Phase 2a: Estimate the median PSA progression-free survival (PSA PFS) of the combination of BXCL701 and PEMBRO in Cohort A and B.

    The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro

    Measured: up to 36 months

  3. Phase 2a: Estimate the median overall survival (OS) of the combination of BXCL701 and PEMBRO in Cohort A and B.

    The median time frame with overall survival with the use of BXCL701 in combination with Pembro

    Measured: up to 36 months

  4. Phase 2a: Estimate the median duration of response (DOR) of the combination of BXCL701 and PEMBRO in Cohort A and B.

    The timeframe in which the tumor reacts to BXCL701 in combination with Pembro

    Measured: up to 36 months

  5. Phase 2a: Determine the risk profile of the use of BXCL701 in combination with PEMBRO.

    Determines the frequency and severity of known and unknown adverse events with the use of BXCL701 in combination with Pembro

    Measured: up to 36 months

  6. Phase 2a: Assess population pK of BXCL701

    To assess the population pharmacokinetics of BXCL701 using sparse pharmacokinetic sampling.

    Measured: Up to 36 months

  7. Phase 2a: Assess pharmacodynamic profile of BXCL701 and Pembro

    To assess the pharmacodynamic profile of the combination of BXCL701 and PEMBRO by measuring relevant effects on those cytokines previously shown to be modulated by BXCL701 in humans.

    Measured: Up to 36 months

  8. Phase 2b: Estimate the CRR, OS, duration response, rPFS and PSA PFS of the BXCL701+Pembro.

    To estimate the CRR, OS, duration of response, rPFS, and PSA PFS of the BXCL701 + PEMBRO combination and monotherapy in Cohort A and B, respectively. Composite response rate is defined as achieving 1 or more of the following:

    • Objective response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
    • 50% or greater PSA decline from baseline.

    Measured: Up to 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Apr 2019
  2. Study start12 Feb 2019
  3. Primary completion31 Oct 2023
  4. Study completion31 Aug 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
98 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03910660
Sponsor's protocol ID
BXCL701-201
Status last verified
May 2026
First submitted
4 Jan 2019
Last updated
15 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Aggarwal R, Zhang J, Monk P, Zhu X, Jones R, Linch M, Costin D, de Bono J, Karsh LI, Petrylak DP, Zhang L, Deshpande R, Borderies P, Huang J, O'Neill V, Donkor M, Tagawa S. Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer. J Immunother Cancer. 2026 May 11;14(5):e014242. doi: 10.1136/jitc-2025-014242.

    PubMed 42114950

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing BXCL701 plus Pembrolizumab and BXCL701 monotherapy in people with Prostate Cancer and Neuroendocrine Tumors, run by BioXcel Therapeutics Inc at 12 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 33 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in United States, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Phase 2a: Estimate the composite response rate of the combination of BXCL701 + PEMBRO (time frame: up to 36 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03910660, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in